Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3693-8448
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.04 million
Profitability
Miscellaneous
Employees17
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable
Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions
What is Galmed Pharmaceuticals' stock symbol?
Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."
How were Galmed Pharmaceuticals' earnings last quarter?
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) announced its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.11. View Galmed Pharmaceuticals' Earnings History.
When is Galmed Pharmaceuticals' next earnings date?
What price target have analysts set for GLMD?
5 brokers have issued 12-month price targets for Galmed Pharmaceuticals' stock. Their forecasts range from $10.00 to $59.00. On average, they expect Galmed Pharmaceuticals' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 586.5% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.
What is the consensus analysts' recommendation for Galmed Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.
What are Wall Street analysts saying about Galmed Pharmaceuticals stock?
Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (11/12/2019)
- 2. Maxim Group analysts commented, "Galmed reported 2Q19 with a net loss of ($4.2M) and ended the period with $83.6M in cash." (8/6/2019)
- 3. HC Wainwright analysts commented, "We maintain our Buy rating of ATEC and raise our 12-month price target to $6.00 per share, up from $4.00. We derive our price target based on: (1) an EV-to-sales multiple analysis assuming 10% discount rate and using a 3.0x multiple on projected 2027 sales of $455M; and (2) a discounted cash flow analysis using the projected free cash flow to the firm through 2027 and assuming a 10% discount rate and a 3% terminal growth rate. Using the average of the two methods, we arrive at a 12-month price target of $5.80 per share, which we round to $6.00." (8/6/2019)
Has Galmed Pharmaceuticals been receiving favorable news coverage?
News stories about GLMD stock have been trending very negative recently, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Galmed Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Galmed Pharmaceuticals.
Are investors shorting Galmed Pharmaceuticals?
Galmed Pharmaceuticals saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 403,700 shares, an increase of 8.5% from the September 15th total of 372,200 shares. Based on an average daily volume of 83,400 shares, the short-interest ratio is presently 4.8 days. Currently, 2.7% of the company's stock are sold short. View Galmed Pharmaceuticals' Current Options Chain.
Who are some of Galmed Pharmaceuticals' key competitors?
Some companies that are related to Galmed Pharmaceuticals include Innate Pharma (IPHYF), CymaBay Therapeutics (CBAY), Magenta Therapeutics (MGTA), DURECT (DRRX), Lannett (LCI), Arcus Biosciences (RCUS), Lexicon Pharmaceuticals (LXRX), Provention Bio (PRVB), Kiniksa Pharmaceuticals (KNSA), ProQR Therapeutics (PRQR), Clovis Oncology (CLVS), MediciNova (MNOV), AMAG Pharmaceuticals (AMAG), Beyondspring (BYSI) and Assembly Biosciences (ASMB).
What other stocks do shareholders of Galmed Pharmaceuticals own?
Who are Galmed Pharmaceuticals' key executives?
Galmed Pharmaceuticals' management team includes the folowing people:
- Mr. Allen Baharaff, Chairman, CEO & Pres (Age 54)
- Mr. Yohai Stenzler, CFO & Controller (Age 36)
- Mr. Guy Nehemya, Chief Operating Officer (Age 34)
- Dr. Liat Hayardeny, Chief Scientific Officer (Age 52)
- Dr. Tali Gorfine, Chief Medical Officer (Age 49)
Who are Galmed Pharmaceuticals' major shareholders?
Galmed Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ibex Investors LLC (4.54%).
Which major investors are buying Galmed Pharmaceuticals stock?
GLMD stock was purchased by a variety of institutional investors in the last quarter, including Ibex Investors LLC.
How do I buy shares of Galmed Pharmaceuticals?
Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Galmed Pharmaceuticals' stock price today?
One share of GLMD stock can currently be purchased for approximately $4.37.
How big of a company is Galmed Pharmaceuticals?
Galmed Pharmaceuticals has a market capitalization of $91.86 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.View Additional Information About Galmed Pharmaceuticals.
What is Galmed Pharmaceuticals' official website?
How can I contact Galmed Pharmaceuticals?
Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.
MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
